Back to Search Start Over

A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.

Authors :
Hess J
Unger K
Maihoefer C
Schüttrumpf L
Wintergerst L
Heider T
Weber P
Marschner S
Braselmann H
Samaga D
Kuger S
Pflugradt U
Baumeister P
Walch A
Woischke C
Kirchner T
Werner M
Werner K
Baumann M
Budach V
Combs SE
Debus J
Grosu AL
Krause M
Linge A
Rödel C
Stuschke M
Zips D
Zitzelsberger H
Ganswindt U
Henke M
Belka C
Source :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Mar 01; Vol. 25 (5), pp. 1505-1516. Date of Electronic Publication: 2018 Aug 31.
Publication Year :
2019

Abstract

Purpose: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is associated with unfavorable prognosis, while independent prognostic markers remain to be defined.<br />Experimental Design: We retrospectively performed miRNA expression profiling. Patients were operated for locally advanced HPV-negative HNSCC and had received radiochemotherapy in eight different hospitals (DKTK-ROG; n = 85). Selection fulfilled comparable demographic, treatment, and follow-up characteristics. Findings were validated in an independent single-center patient sample (LMU-KKG; n = 77). A prognostic miRNA signature was developed for freedom from recurrence and tested for other endpoints. Recursive-partitioning analysis was performed on the miRNA signature, tumor and nodal stage, and extracapsular nodal spread. Technical validation used qRT-PCR. An miRNA-mRNA target network was generated and analyzed.<br />Results: For DKTK-ROG and LMU-KKG patients, the median follow-up was 5.1 and 5.3 years, and the 5-year freedom from recurrence rate was 63.5% and 75.3%, respectively. A five-miRNA signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306, and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG [hazard ratio (HR) 4.42; 95% confidence interval (CI), 1.98-9.88, P < 0.001], which was confirmed in LMU-KKG (HR 4.24; 95% CI, 1.40-12.81, P = 0.005). The signature also predicted overall survival (HR 3.03; 95% CI, 1.50-6.12, P = 0.001), recurrence-free survival (HR 3.16; 95% CI, 1.65-6.04, P < 0.001), and disease-specific survival (HR 5.12; 95% CI, 1.88-13.92, P < 0.001), all confirmed in LMU-KKG data. Adjustment for relevant covariates maintained the miRNA signature predicting all endpoints. Recursive-partitioning analysis of both samples combined classified patients into low ( n = 17), low-intermediate ( n = 80), high-intermediate ( n = 48), or high risk ( n = 17) for recurrence ( P < 0.001).<br />Conclusions: The five-miRNA signature is a strong and independent prognostic factor for disease recurrence and survival of patients with HPV-negative HNSCC. See related commentary by Clump et al., p. 1441 .<br /> (©2018 American Association for Cancer Research.)

Details

Language :
English
ISSN :
1557-3265
Volume :
25
Issue :
5
Database :
MEDLINE
Journal :
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Type :
Academic Journal
Accession number :
30171046
Full Text :
https://doi.org/10.1158/1078-0432.CCR-18-0776